Corporate
Working with International Incubators Medtech Makers Labs have developed a network of global partners
Discover more
Funding & Investment
1
We operate as a Limited Partner (LP) within carefully selected investment funds, positioning capital alongside experienced General Partners while maintaining strategic visibility over underlying assets.
Our approach is highly selective and thesis-driven, ensuring alignment with sectors where we can add asymmetric value—particularly in medtech, clinical development, and cross-border scaling. We structure participation to mirror family office priorities: capital preservation first, followed by disciplined downside protection and access to differentiated deal flow.
Through this model, we align investment horizons, liquidity expectations, and governance with family office strategies, often co-investing directly into high-conviction opportunities emerging from the fund. This creates a dual advantage—portfolio diversification at the fund level, combined with targeted exposure to scalable, IP-rich assets that meet institutional return thresholds.
2026
14 Companies are already supported by MedTech Makers Lab
"A pitch deck or information memorandum is not a business plan"
Business Planning & Implementatiom
2
Our advisory model is anchored in enterprise growth, working alongside founders to co-develop their companies rather than operating as a detached consultant. We engage directly in shaping strategy, governance, and execution, ensuring that each decision aligns with long-term value creation and scalability.
This includes hands-on involvement in structuring the business, refining the commercial model, and aligning clinical, regulatory, and financial pathways.
Our compensation is structured through warrants, earned over time and directly tied to the growth in enterprise value, ensuring full alignment with founders and investors. The outcome is a partnership-driven approach that builds institutional-grade businesses, not just standalone projects.
Private Equity Approach
3
Our private equity approach is built on actively developing high-growth companies, not passively investing in them. We work alongside leadership teams to drive new product development, ensuring innovation is commercially viable, clinically relevant, and scalable. In parallel, we design and execute merger and acquisition strategies that accelerate growth, consolidate market position, and unlock strategic synergies.
Every intervention is structured with a clear value creation plan, aligning operational execution with investor-grade performance metrics. This disciplined approach culminates in a defined exit strategy—whether through acquisition, strategic sale, or capital markets—maximising enterprise value and investor returns.
We operate with institutional discipline and hands-on execution, bridging the gap between innovation and realisable value. The result is a portfolio of businesses engineered for scale, resilience, and premium exit outcomes.
